Skip to content

Débat Public

Are you for or against?

Pharmaceutical Logistics: The Keys to a Reliable and Secure Supply Chain

A temperature excursion affecting a batch of vaccines does not automatically mean it must be destroyed. This is still not fully understood in many processes…

Technicienne en logistique pharmaceutique scannant des médicaments dans un entrepôt réfrigéré sécurisé
5 min read

A temperature excursion affecting a vaccine batch does not automatically mean it must be destroyed. This reality, still poorly understood in many operational processes, sums up the constant tension in pharmaceutical logistics: balancing patient protection against avoidable waste, based on documented scientific data.

The pharmaceutical supply chain operates under strict regulatory constraints, but it is rigorous technical assessment—not a conservative reflex—that ensures both safety and efficiency.

Temperature excursions and stability data: making informed decisions instead of destroying by default

One of the costliest reflexes in pharmaceutical logistics is to reject a batch as soon as a temperature threshold is exceeded, without consulting the product’s stability data. ICH guidelines (Q1A, Q1E) require manufacturers to document how each medicinal product behaves under different thermal stress conditions. This data exists. Logistics operators rarely use it in real time.

A documented excursion may not affect a medicine’s quality if its duration and magnitude remain within the limits validated by stability studies. The assessment is based on calculating the mean kinetic temperature (MKT) and comparing it with known degradation profiles.

The challenge is not scientific but organizational. Supply chain stakeholders with continuous monitoring data (onboard data loggers, IoT) can produce an assessment dossier that supports a decision. Those relying on spot checks lack the level of detail needed to justify keeping a batch. The quality of logistics data directly determines the ability to make informed decisions.

Specialized resources document these assessment processes as applied to the cold chain, such as https://pharmalog.fr, which covers excursion management protocols in an operational context.

Pharmaceutical supply chain manager overseeing the delivery of a refrigerated van at the loading dock

Pharmaceutical serialization: verification requirements vary by territory

The EU Falsified Medicines Directive requires a unique identifier and an anti-tampering device for covered medicines in the European Union, verified at the point of dispensing. This framework may appear harmonized, but that changes as soon as the supply chain crosses certain borders.

Since January 2025, the new Windsor Framework arrangements have ended the application of the European verification system in the United Kingdom. A supply chain serving both the EU and the UK market must manage two separate serialization regimes, with separate verification databases and different reporting obligations.

This fragmentation has direct implications for distributors’ IT architecture. Warehouse management systems (WMS) must incorporate routing rules based on the batch’s final destination, not just the product. 3PL providers operating across borders must maintain interfaces with the national verification hubs in every territory they serve.

  • In the EU, verification takes place at the point of dispensing through the EMVS, with the unique identifier decommissioned when the medicine is dispensed
  • In the UK, the post-Windsor Framework regime no longer requires this verification, creating an asymmetry for batches destined for multiple markets
  • For exports outside the EU, serialization requirements vary widely by market (a specific federal framework in the United States, local regulations elsewhere)

Supply chain resilience: a factor in public procurement

The European Critical Medicines Act proposal, presented on 11 March 2025, marks a turning point in how public buyers will assess their suppliers. Diversifying sources of supply could become a selection criterion, alongside price and lead times.

The proposal builds on work by the EMA and national authorities to identify vulnerabilities. The aim is to pinpoint medicines whose production depends on a limited number of sites or active ingredient suppliers concentrated in third countries. We are seeing this analysis shift from a general approach to resilience toward targeted, product-by-product audits.

The text also provides for strategic industrial projects and joint procurement mechanisms. For logistics providers, the implications are tangible: public tenders will likely include documentation requirements covering upstream traceability, mapping of tier 2 suppliers, and the ability to switch suppliers if a production site fails.

Early notification of supply disruptions

The European compromise on pharmaceutical reform, which is separate from the legislation already in force, provides for shortage prevention plans for certain medicines and notification of supply interruptions with up to six months’ notice. This approach shifts crisis management toward early detection.

For logistics operators, this means reporting stock and flow information well beyond the usual scope. A provider handling only the last mile will need to supply us with data that health authorities can use, at a level of detail and frequency of updates beyond current practice.

Two quality control specialists inspecting serialized pharmaceutical packaging in a GMP-certified cleanroom

Temperature-controlled storage and transport: where breakdowns happen

The pharmaceutical cold chain is about more than choosing between 2-8 °C and room temperature. Innovative therapies (gene therapies, CAR-T) require cryogenic conditions of -150 °C or below, with extremely short transit windows. The logistics for these products rely on active liquid nitrogen or dry ice containers, whose availability remains an operational bottleneck.

  • Conventional products (2-8 °C) rely on passive packaging qualified for defined transit times, with data loggers to document the cold chain
  • Controlled room temperature products (15-25 °C) are frequently exposed to excursions in summer, making the stability data discussed above especially important
  • Advanced therapies require real-time coordination between the production site, carrier, and treatment center, with shelf lives sometimes under 24 hours

The most vulnerable link remains the transfer between the vehicle and the storage area, when the product leaves a controlled environment for a loading dock where the temperature is not always controlled. Receiving protocols that require a temperature check when the package is opened, rather than when it arrives at the dock, significantly reduce the risk of losing thermal traceability.

The robustness of a pharmaceutical supply chain is measured by its ability to document every link, not to eliminate all risk. Ongoing European regulatory changes are driving greater transparency, from active ingredient manufacturing to the final stretch before the patient. Operators investing today in more granular logistics data are positioning themselves around the criterion that will matter as much as price tomorrow: proof of reliability.

Pharmaceutical Logistics: The Keys to a Reliable and Secure Supply Chain